Assessment of colorectal cancer treatment is long overdue in Brazil
| May 20, 2016
Assessing costs for patients in the treatment of metastatic colorectal cancer is the objective of one study from Evidências - Kantar Health that will be presented at the annual meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). The event takes place in Washington, D.C., May 21-25.
Only one study of this kind exists in the literature, making this poster an innovative piece of research and the first to specifically address metastatic colorectal cancer. The study was based on treatment costs passed on to patients when they requested reimbursement from the High Complexity Procedures Authorization System (APAC), part of the Brazilian public healthcare system (SUS). APAC has a reimbursement value for each indication of the disease treatment; a survey on treatments available in Brazil and costs of treatments per month was conducted based on the value of the treatment of metastatic colorectal cancer.
“This analysis is a great starting point for a long-needed discussion on the basic financing mechanisms in the Brazilian public healthcare system,” says Teresa Lemmer, pharmacoeconomics analyst of Evidências - Kantar Health and one of the authors of the study. “We intend, with this poster, to contribute to increasing the availability of resources in hospitals and, consequently, to improve access to treatment of patients with metastatic colorectal cancer in Brazil.”
ISPOR is one of the most important scientific dissemination channels of pharmacoeconomics and outcomes research. Besides being a public non-profit organization for educational and scientific purposes, ISPOR promotes pharmacoeconomics science and the outcomes research, and facilitates the translation of this research into useful information for decision makers in the area of healthcare. The company has more than 9,500 members in 114 countries. ISPOR promotes three meetings annually, conducted in North America, Europe and Latin America or Asia.